Figure 2.

Facility-level rates of HbA_1c measures for selected performance groups based on facility rankings from the OOR measure. The study population included patients with diabetes and an HbA_1c value available in FY 2013 who were taking any antihyperglycemic agent other than metformin alone within 60 days before their last HbA_1c in FY 2013 and who had at least one of the studied comorbidities. Facilities were ranked based on the OOR measure (HbA_1c <7% [53 mmol/mol]; HbA_1c >9% [75 mmol/mol]). Lower rates correspond to better performance. Three groups were presented: the best-performing 10%, median-performing 10%, and worst-performing 10%.